50 results
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
25 Apr 24
Current report (foreign)
4:06pm
the research and development of new drugs in this field in the future. What kind of feedback has the Everest team received from the early access patient … 60.5 million and SEK 15.2 million for the year ended December 31, 2023 and 2022, respectively. Research and development expenses Research
6-K
EX-99.2
8og 58t5vaj
21 Feb 24
Calliditas Year-end report, January – December 2023
4:05pm
6-K
iezd sgcebb
27 Dec 23
Current report (foreign)
4:05pm
6-K
EX-99.1
br4k ks43
7 Nov 23
Interim Report January – September 2023 Q3
4:05pm
6-K
EX-99.1
xjdf0vdl
5 Oct 23
Current report (foreign)
4:05pm
6-K
EX-99.1
1emtzv6au3gbqzjw
17 Aug 23
Filing for full approval of TARPEYO
4:05pm
S-8
EX-4.1
2ljss116
12 Jun 23
Registration of securities for employees
4:06pm
6-K
EX-99.1
mcgw6
16 May 23
Current report (foreign)
4:05pm
6-K
EX-99.1
ot37 8s8ip7h
28 Apr 23
Current report (foreign)
4:05pm
6-K
EX-99.1
60lvndbp9so1q jsi4or
14 Nov 22
Current report (foreign)
5:25pm
6-K
EX-99.1
v29m4a3 k0d51p
19 Aug 22
Interim Report January 1ST – June 30TH 2022
7:55am
F-3
ldndshfn
28 Jun 22
Shelf registration (foreign)
4:49pm